EMA Wants Panexcell-Tested Generics Suspended; Spares Yondelis
The European Medicines Agency says that available evidence from a discontinued study does not call into question PharmaMar/Janssen’s Yondelis in its currently authorized uses. But in a separate recommendation it says that bioequivalence studies on generic drugs conducted by CRO Panexcell might be flawed.
You may also be interested in...
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.
New medicines under evaluation at the European Medicines Agency.